Biosimilar DTC Outlook—Is 2020 the Year of Opportunity?

“With momentum in Washington and increased advocacy from patients and payers, this could be the year of opportunity biosimilar manufacturers have been waiting for.” – Jeff Greene, VP, Strategy

View the full article here